We are live on ! Find out more
IMVT icon

Immunovant
IMVT

87 hedge funds and large institutions have $696M invested in Immunovant in 2020 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 29 increasing their positions, 11 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

259% more capital invested

Capital invested by funds: $194M → $696M (+$502M)

164% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 11

118% more funds holding

Funds holding: 40 → 87 (+47)

20.02% more ownership

Funds ownership: 23.21% → 43.23% (+20%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
87
Holders Change
+47
Holders Change %
+117.5%
% of All Funds
1.78%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
47
Increased
29
Reduced
11
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$36.2M
2
BlackRock
BlackRock
New York
+$30M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$28.8M
4
PC
Polar Capital
United Kingdom
+$28.3M
5
RI
RTW Investments
New York
+$27.7M

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$12M
2
MP
Mangrove Partners
Connecticut
-$9.46M
3
GTC
Ghost Tree Capital
New York
-$3.96M
4
WP
Woodline Partners
California
-$2.02M
5
BFM
Boothbay Fund Management
New York
-$1.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$5.2M +$4.2M +195,896 +1,103%
N
27
Nuveen
North Carolina
$4.61M +$4.05M +189,151 New
SCM
28
Suvretta Capital Management
New York
$4.09M +$2.82M +131,784 +365%
Charles Schwab
29
Charles Schwab
California
$3.79M +$3.34M +155,703 New
SCM
30
Sio Capital Management
New York
$3.71M +$821K +38,317 +34%
Goldman Sachs
31
Goldman Sachs
New York
$3.67M +$1.64M +76,695 +104%
Invesco
32
Invesco
Georgia
$3.65M +$3.21M +149,849 New
Point72 Asset Management
33
Point72 Asset Management
Connecticut
$3.64M +$2.71M +126,251 +540%
CS
34
Candriam SCA
Luxembourg
$3.41M +$3M +140,000 New
MP
35
Mangrove Partners
Connecticut
$3.17M -$9.46M -441,635 -77%
PHP
36
Parkman Healthcare Partners
Connecticut
$3.05M +$1.82M +85,000 +212%
Deutsche Bank
37
Deutsche Bank
Germany
$2.88M +$2.53M +118,097 New
PI
38
Putnam Investments
Massachusetts
$2.71M +$2.38M +111,207 New
AllianceBernstein
39
AllianceBernstein
Tennessee
$2.65M +$1.15M +53,505 +97%
SFM
40
Sphera Funds Management
Israel
$2.56M +$1.84M +85,968 +452%
PM
41
Prosight Management
Texas
$2.33M -$556K -25,929 -21%
Aviva
42
Aviva
United Kingdom
$2.19M +$1.92M +89,738 New
Bank of New York Mellon
43
Bank of New York Mellon
New York
$1.83M +$1.61M +75,104 New
PHS
44
PFM Health Sciences
California
$1.64M +$1.44M +67,163 New
Marshall Wace
45
Marshall Wace
United Kingdom
$1.55M +$1.12M +52,475 +475%
Swiss National Bank
46
Swiss National Bank
Switzerland
$1.26M +$1.11M +51,600 New
GPCM
47
Granite Point Capital Management
Massachusetts
$1.22M +$321K +15,000 +43%
Wells Fargo
48
Wells Fargo
California
$1.05M +$923K +43,080 New
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$1.03M +$907K +42,321 New
SI
50
Sofinnova Investments
California
$987K +$868K +40,513 New
1
2
3 4

IMVT Hedge Fund Activity: Q2 2020 in Review

87 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q2 2020, worth a combined $696M — up 259% from $194M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new IMVT positions and 0 closed out — a net gain of 47 holders — while 29 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $36.2M. The largest seller was Ikarian Capital, cutting an estimated $12M.

  • 87 institutional investors held Immunovant (IMVT) as of Q2 2020, up from 40 in Q1 2020.
  • Funds reported $696M of Immunovant stock for Q2 2020, up 259% quarter-over-quarter.
  • 47 funds opened new Immunovant positions in Q2 2020 and 0 closed out, a net change of +47 holders.
  • The largest Immunovant buyer in Q2 2020 was Vanguard Group, an estimated $36.2M added.
  • The largest Immunovant seller in Q2 2020 was Ikarian Capital, an estimated $12M sold.

Based on aggregated 13F filings for Q2 2020.